Finanzas de Thermo Fisher Scientific Inc (TMO)TMOThermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. (TMO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service, accounting for 43.1% of total sales, equivalent to $5.17B. Other significant revenue streams include Consumables and Instruments. Understanding this composition is critical for investors evaluating how TMO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Thermo Fisher Scientific Inc. maintains a gross margin of 38.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.29%, while the net margin is 14.23%. These profitability ratios, combined with a Return on Equity (ROE) of 13.37%, provide a clear picture of how effectively TMO converts its operational activities into shareholder value.

In the context of the broader market, TMO competes directly with industry leaders such as ABT and DHR. With a market capitalization of $250.15B, it holds a leading position in the sector. When comparing efficiency, TMO's gross margin of 38.50% stands against ABT's 50.77% and DHR's 59.34%. Such benchmarking helps identify whether Thermo Fisher Scientific Inc. is trading at a premium or discount relative to its financial performance.

Thermo Fisher has shown consistent revenue growth, with Q3 2026 revenue reported at $12.14 billion, a 10% year-over-year increase. The gross margin is currently at 38.50%, and the forward P/E ratio is 24.15, indicating reasonable valuation relative to its growth prospects.